Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: Population-based record-linkage study

British Journal of Cancer

Volumn 108, Issue 1, 2013, Pages 193-198

  Seminog, O O ^a   Goldacre, M J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

benign tumours; malignant neoplasm; Neurofibromatosis; record linkage; risk of cancer

Indexed keywords

ARTICLE; BONE CANCER; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COLON CANCER; ESOPHAGUS CANCER; FEMALE; HOSPITAL ADMISSION; HUMAN; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MORTALITY; NERVOUS SYSTEM TUMOR; NEUROFIBROMATOSIS; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; RISK FACTOR; STOMACH CANCER; THYROID CANCER; UNITED KINGDOM;

FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NERVOUS SYSTEM NEOPLASMS; NEUROFIBROMATOSES; POPULATION SURVEILLANCE; RISK FACTORS;

EID: 84872617743     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.535     Document Type: Article

References (31)

1. Breslow N, Day N (1987) Statistical methods in cancer research. Volume II-the design and analysis of cohort studies. IARC Sci Publ 82: 91-97.
2. Burns EM, Rigby E, Mamidanna R, Bottle A, Aylin P, Ziprin P, Faiz OD (2011) Systematic review of discharge coding accuracy. J Public Health 34: 138-148.
3. Duong TA, Sbidian E, Valeyrie-Allanore L, Vialette C, Ferkal S, Hadj-Rabia S, Glorion C, Lyonnet S, Zerah M, Kemlin I, Rodriguez D, Bastuji-Garin S, Wolkenstein P (2011) Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France. Orphanet J Rare Dis 6: 18.
4. Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis. J Med Genet 39: 311-314.
5. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet 152A: 327-332.
6. Evans DG, O'Hara C, Wilding A, Ingham SL, Howard E, Dawson J, Moran A, Scott-Kitching V, Holt F, Huson SM (2011) Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet 19: 1187-1191.
7. Ferner RE, Hughes RA, Hall SM, Upadhyaya M, Johnson MR (2004) Neurofibromatous neuropathy in neurofibromatosis 1 (NF1). J Med Genet 41: 837-841.
8. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A (2007) Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44: 81-88.
9. Ferner RE (2010) The neurofibromatoses. Pract Neurol 10: 82-93.
10. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ (2010) Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies. J Neurol Neurosurg Psychiatry 81: 215-221.
11. Gill L, Goldacre M (2003) English national record linkage of hospital episode statistics and death registration records. Report to the Department of Health. Oxford: Unit of Health-Care Epidemiology, University of Oxford.
12. Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Flint J (2007) Cancer in people with depression or anxiety: record-linkage study. Soc Psychiatry Psychiatr Epidemiol 42: 683-689.
13. Goldacre MJ, Wotton CJ, Yeates DG (2009) Cancer and immune-mediated disease in people who have had meningococcal disease: record-linkage studies. Epidemiol Infect 137: 681-687.
14. Imaizumi Y (1995) Mortality of neurofibromatosis in Japan, 1968-1992. J Dermatol 22: 191-195.
15. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K (2005) The NF1 tumor ressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 102: 8573.
16. Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, Rioth MJ, McClatchey A, Ryeom S, Cichowski K (2008) TORC1 is essential for NF1-associated malignancies. Curr Biol 18: 56-62.
17. Jouhilahti E, Peltonen S, Heape AM, Peltonen J (2011) The pathoetiology of neurofibromatosis 1. Am J Pathol 178: 1932-1939.
18. Masocco M, Kodra Y, Vichi M, Conti S, Kanieff M, Pace M, Frova L, Taruscio D (2011) Mortality associated with neurofibromatosis type 1: a study based on Italian death certificates (1995-2006). Orphanet J Rare Dis 6: 11.
19. Matsui I, Tanimura M, Kobayashi N, Sawada T, Nagahara N, Akatsuka J (1993) Neurofibromatosis type 1 and childhood cancer. Cancer 72: 2746-2754.
20. Rasmussen SA, Yang Q, Friedman JM (2001) Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 68: 1110-1118.
21. Sharif S, Moran A, Huson SM, Iddenden R, Shenton A, Howard E, Evans DG (2007) Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 44: 481-484.
22. Sorensen SA, Mulvihill JJ, Nielsen A (1986) Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med 314: 1010-1015.
23. Stiller CA, Chessells JM, Fitchett M (1994) Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 70: 969-972.
24. Tucker T, Schnabel C, Hartmann M, Friedrich RE, Frieling I, Kruse HP, Mautner VF, Friedman JM (2009) Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet 46: 259-265.
25. Viskochil D, Buchberg AM, Xu G, Cawthon RM, Stevens J, Wolff RK, Culver M, Carey JC, Copeland NG, Jenkins NA, White R, O'Connell P (1990) Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62: 187.
26. Walker L, Thompson D, Easton D, Ponder B, Ponder M, Frayling I, Baralle D (2006) A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 95: 233-238.
27. Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain JW, Brereton A, Nicholson J, Mitchell AL, Brownstein BH, Collins FS (1990) Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249: 181-186.
28. World Health Organization (1992) International Statistical Classification of Diseases and Related Health Problems, 10th revision: Volume 1: 844. World Health Organization: Geneva.
29. Zinnamosca L, Petramala L, Cotesta D, Marinelli C, Schina M, Cianci R, Giustini S, Sciomer S, Anastasi E, Calvieri S, De Toma G, Letizia C (2011) Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects. Arch Dermatol Res 303: 317-325.
30. Zöller M, Rembeck B, Akesson HO, Angervall L (1995) Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg, Sweden. Acta Derm Venereol 75: 136-140.
31. Zöller ME, Rembeck B, Odén A, Samuelsson M, Angervall L (1997) Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 79: 2125-2131.